China's 3SBio, Highlight Capital, Yonghua back $50m Verseau Therapeutics round

Photo by Louis Reed on Unsplash

Verseau Therapeutics that develops novel, first-in-class immunotherapies on Monday announced the completion of a $50-million new round of financing.

Hong Kong-listed biotech firm 3SBio, Shanghai-based investment company Highlight Capital, and Chinese private equity firm Yonghua Capital invested in the new round, according to a company statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter